Objective:

to assess whether the punctual dose prescription technique, point A, is adequate for dose estimation in CTV-HR using 3D gynecological brachytherapy.

Methods:

treatment plans were collected for 35 patients with stage IB2-IVA (140 fractions or treatment plans) cervical cancer treated between 2019 and 2021, whose prescribed dose was 28Gy in 4 fractions. Points A were reconstructed, the prescribed dose was normalized to 100% isodose to compare with the doses in CTV- HR(D90%).

Results:

the average dose absorbed at CTV-HR(D90%) was 88.82 ±2.53 Gy and when normalizing the isodose of 100% at point A, average dose at CTV-HR(D90%) was obtained. of 99.3±5.85Gy. This average dose variation to the CTV-HR(D90%) represented an increase of 18%, resulting in 80% of the treatments corresponding to 28 patients falling outside the acceptable variation of the EMBRACE II protocol and only 20% of the treatments corresponding to 7 patients are within the range of the acceptable variation of the protocol in question.

Conclusions:

the dose prescription technique at point A clinically translates into an overdose of tumor and healthy tissue (rectum, sigmoid, bladder and intestine).

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )